Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Liquid Chromatography-Mass Spectrometry

By Drug Discovery Trends Editor | June 3, 2010

EquanThermo Fisher Scientific Inc. announced the launch of  the Thermo Scientific EQuan MAX an automated  high throughput Liquid Chromatography-Mass Spectrometry (LC-MS) solution for the analysis of contaminants in water and beverages. This innovative system with high resolution and accurate mass (HRAM) boasts new screening and quantitative capabilities that provide enhanced system flexibility and productivity.

EQuan MAX combines with the power of the Exactive LC-MS system. The Exactive is a high resolution benchtop LC-MS system, powered by Oribtrap technology, designed for high throughput screening of target and non-target compounds. In addition, the EQuan MAX can also be used with the full range of Thermo Scientific TSQ series triple stage quadrupole mass spectrometers.

“Exposure to chemical contaminants in beverages and water is a significant and growing concern,” said Dipankar Ghosh, strategic marketing manager for environmental and food safety solutions at Thermo Fisher. “As new contaminants emerge, labs performing water and beverage analysis will be challenged to detect and quantify both target and non-target contaminants, and to do it faster than ever before. EQuan MAX enables laboratories to do both.”

EQuan MAX is a comprehensive solution for the analysis of pesticides, pharmaceuticals, personal care products, endocrine disruptors and perfluorinated compounds in environmental water, drinking water and beverages.  With EQuan MAX, samples are directly injected for LC/MS analysis, eliminating the need for off-line sample preconcentration. Its unique online sample preparation technique reduces analysis time from days to minutes, designed to increase lab productivity.

Its large injection volume (1-20mL) improves detection limits over conventional LC-MS analysis. In addition to large injection volumes, EQuan MAX now supports injection volumes as low as 1µL. Switching between injection volumes can be automated for overnight operation and increased productivity, without the need to manually change plumbing configurations.

The new EQuan MAX autosampler and plumbing provide out-of-the-box compatibility with the Thermo Scientific Accela 600 high pressure liquid chromatography (HPLC) and Thermo Scientific Accela 1250 ultra-high pressure liquid chromatography (U-HPLC) systems. This enables users to take full advantage of the most advanced Thermo Scientific HPLC technology to achieve fast, efficient chromatographic separations over an expansive range of flow rates and pressures. The new autosampler is also more compact, reducing total system footprint from approximately 5 to 2.5 square feet, saving valuable lab space.
EQuan MAX can be used with Thermo Scientific TraceFinder software which provides an extensive menu of preconfigured methods and report formats that make screening for routine contaminants simple. A point-and-click interface prompts the user through the steps needed to create methods. The unique ability of TraceFinder™ to perform structural confirmation and library matching enables it to confirm and quantitate hundreds of compounds in a single experiment, increasing sample throughput. To ensure that data is not compromised and that changes are clearly recorded, TraceFinder offers data security with a rights-based user log-in system that limits access to methods and data.

Thermo Fisher Scientific Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50